<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066790</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1901</org_study_id>
    <nct_id>NCT04066790</nct_id>
  </id_info>
  <brief_title>Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer</brief_title>
  <official_title>A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of pyrotinib in combination with
      nab-paclitaxel or trastuzumab with nab-paclitaxel as neoadjuvant therapy in early stage or
      locally advanced HER2-positive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study evaluate the pathological complete response rate, event-free survival, disease-free
      survival, overall survival and safety of pyrotinib in combination with nab-paclitaxel or
      trastuzumab with nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced
      HER2-positive breast cancer. Patients will receive 4 cycles of pyrotinib in combination with
      nab-paclitaxel or 4 cycles of trastuzumab with nab-paclitaxel as neoadjuvant therapy, then
      undergo surgery, then receive 4 cycles of epirubicin in combination with cyclophosphamide,
      then complete 1 year of trastuzumab.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We terminated this trial and initiated a new one including pertuzumab.
  </why_stopped>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Total Pathologic Complete Response (tpCR)</measure>
    <time_frame>Cycle 4 . The duration of one treatment cycle is 21 days.</time_frame>
    <description>tpCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer [AJCC] staging system).The duration of one treatment cycle is 21 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Breast Pathologic Complete Response (bpCR)</measure>
    <time_frame>Cycle 4 . The duration of one treatment cycle is 21 days.</time_frame>
    <description>bpCR is defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system).The duration of one treatment cycle is 21 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Cycle 4 . The duration of one treatment cycle is 21 days.</time_frame>
    <description>Percentage of Participants With Complete Response, Partial Response, Stable Disease, or Progressive Disease During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. The duration of one treatment cycle is 21 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>From Baseline to EFS event or date last known to be alive and event-free (up to 5 years)</time_frame>
    <description>EFS is defined as the time from randomization to the first documentation of one of the following events: Disease progression (before surgery) as determined by the investigator with use of RECIST v1.1 Any evidence of contralateral disease in situ was not identified as progressive disease; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From surgery to DFS event or date last known to be alive and event-free (up to 5 years)</time_frame>
    <description>DFS was defined as the time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery. Any evidence of contralateral disease in situ was not identified as disease recurrence; Death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From Baseline to OS event or date last known to be alive (up to 5 years)</time_frame>
    <description>OS was defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With At Least One Adverse Event During Treatment Period</measure>
    <time_frame>From randomization to 30 days after completion of study treatment</time_frame>
    <description>The percentage of participants who experienced at least one adverse event during the neoadjuvant period, surgery, adjuvant treatment period.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pyrotinib in combination with nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab in combination with nab-paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.</description>
    <arm_group_label>Pyrotinib in combination with nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.</description>
    <arm_group_label>Pyrotinib in combination with nab-paclitaxel</arm_group_label>
    <arm_group_label>Trastuzumab in combination with nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab</description>
    <arm_group_label>Pyrotinib in combination with nab-paclitaxel</arm_group_label>
    <arm_group_label>Trastuzumab in combination with nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC chemotherapy</intervention_name>
    <description>epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)</description>
    <arm_group_label>Pyrotinib in combination with nab-paclitaxel</arm_group_label>
    <arm_group_label>Trastuzumab in combination with nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.</description>
    <arm_group_label>Pyrotinib in combination with nab-paclitaxel</arm_group_label>
    <arm_group_label>Trastuzumab in combination with nab-paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With signed consent

          -  Histologically confirmed invasive breast carcinoma with a primary tumor size of no
             less than (â‰¥) 2 centimeters (cm) by standard local assessment technique

          -  Breast cancer stage at presentation: stage I-III

          -  HER2-positive breast cancer defined as 3+ score by immunohistochemistry in &gt; 10
             percent (%) of immunoreactive cells or HER2 gene amplification by in situ
             hybridization

          -  Known hormone receptor status (estrogen receptor and/or progesterone receptor)

          -  Eastern Cooperative Oncology Group Performance Status equal to or less than (&lt;=) 1

          -  Baseline left ventricular ejection fracture &gt;= 50% measured by echocardiography

          -  Willing to use highly effective form of nonhormonal contraception while on study and
             for 7 months after end of study treatment for female with fertility or male

          -  Negative serum pregnancy test for women with fertility

          -  Willing to obey the study protocol

        Exclusion Criteria:

          -  Stage IV disease

          -  Previous anti-cancer therapy or radiotherapy for any malignancy

          -  History of other malignancy within 5 years prior to screening, except for
             appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
             Stage I uterine cancer

          -  Concurrent anti-cancer treatment in another investigational trial, including hormone
             therapy, bisphosphonate therapy, or immunotherapy

          -  Major surgical procedure unrelated to breast cancer within 4 weeks prior to
             randomization or from which the participant has not fully recovered

          -  Serious cardiac illness or medical condition

          -  Other concurrent serious diseases that may interfere with planned treatment, including
             severe pulmonary conditions/illness

          -  Any abnormalities in liver, kidney or hematologic function laboratory tests
             immediately prior to randomization

          -  Sensitivity to any of the study medications, any of the ingredients or excipients of
             these medications, or benzyl alcohol

          -  Not able to swallow the drug

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HER2-positive</keyword>
  <keyword>neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

